Pharma-Bio Serv, Inc.
Pharma-Bio Serv, Inc. Fundamental Analysis
Pharma-Bio Serv, Inc. (PBSV) shows weak financial fundamentals with a PE ratio of -150.42, profit margin of -0.00%, and ROE of -0.00%. The company generates $2.0B in annual revenue with weak year-over-year growth of -5.34%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 14.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze PBSV's fundamental strength across five key dimensions:
Efficiency Score
WeakPBSV struggles to generate sufficient returns from assets.
Valuation Score
ModeratePBSV shows balanced valuation metrics.
Growth Score
ModeratePBSV shows steady but slowing expansion.
Financial Health Score
ExcellentPBSV maintains a strong and stable balance sheet.
Profitability Score
WeakPBSV struggles to sustain strong margins.
Key Financial Metrics
Is PBSV Expensive or Cheap?
P/E Ratio
PBSV trades at -150.42 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, PBSV's PEG of 29.46 indicates potential overvaluation.
Price to Book
The market values Pharma-Bio Serv, Inc. at 0.00 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -18467.10 times EBITDA. This is generally considered low.
How Well Does PBSV Make Money?
Net Profit Margin
For every $100 in sales, Pharma-Bio Serv, Inc. keeps $-0.00 as profit after all expenses.
Operating Margin
Core operations generate -15.95 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-0.00 in profit for every $100 of shareholder equity.
ROA
Pharma-Bio Serv, Inc. generates $-0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Pharma-Bio Serv, Inc. generates limited operating cash flow of $-153.61M, signaling weaker underlying cash strength.
Free Cash Flow
Pharma-Bio Serv, Inc. generates weak or negative free cash flow of $-153.61M, restricting financial flexibility.
FCF Per Share
Each share generates $-6.71 in free cash annually.
FCF Yield
PBSV converts -13.42% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-150.42
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
29.46
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.001
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.006
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.03
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.00
vs 25 benchmark
ROA
Return on assets percentage
-0.00
vs 25 benchmark
ROCE
Return on capital employed
-0.03
vs 25 benchmark
How PBSV Stacks Against Its Sector Peers
| Metric | PBSV Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -150.42 | 29.06 | Better (Cheaper) |
| ROE | -0.00% | 646.00% | Weak |
| Net Margin | -0.00% | -44088.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.33 | Strong (Low Leverage) |
| Current Ratio | 4.03 | 4.49 | Strong Liquidity |
| ROA | -0.00% | -15444.00% (disorted) | Weak |
PBSV outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Pharma-Bio Serv, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-58.16%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-104.91%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-114.12%
Industry Style: Defensive, Growth, Innovation
Declining